Loading the records…
Loading the records…
S.3990, the PrEP Access and Coverage Act of 2026, is an early-stage bill that would mandate private insurance coverage of HIV pre-exposure prophylaxis (PrEP) without cost-sharing. If enacted, it would directly benefit Gilead Sciences ($GILD), the dominant manufacturer of PrEP drugs. However, as a referred bill with no committee action since March 2026, market impact is minimal until legislative progress accelerates.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill is procedurally dormant, so no immediate market implications. If it gains traction, expect Gilead ($GILD) to see mild bullish sentiment on potential PrEP demand expansion. Other HIV players like Merck ($MRK) and Johnson & Johnson ($JNJ) are less exposed. Insurers ($UNH) may face headwinds from cost mandates, but the effect is speculative and long-term.
S.3990 was introduced on March 4, 2026, by Sen. Tina Smith (D-MN) with 24 Democratic cosponsors, and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill has not advanced beyond the introductory stage, and its companion bill, HR7853, is similarly stalled in multiple House committees. The legislation would amend the Public Health Service Act and the Affordable Care Act to require private health plans to cover FDA-approved PrEP drugs and associated laboratory and monitoring services without cost-sharing, and prohibit preauthorization requirements.
There is no direct government funding in this bill — it operates through regulatory mandates on insurers, so the 'money trail' is indirect: increased prescription volume for PrEP manufacturers. The primary beneficiary is Gilead Sciences ($GILD), whose Truvada and Descovy products dominate the PrEP market. Merck ($MRK) and Johnson & Johnson ($JNJ) have HIV portfolios but are not leaders in PrEP. Insurers like UnitedHealth ($UNH) could face increased drug costs, but the mandate also reduces long-term HIV treatment costs, making the net effect uncertain.
No convergence signals were identified in the provided context. The bill is a standalone healthcare access measure with no related procurement, executive orders, or other legislative signals in the data.
Structural winners: Gilead Sciences ($GILD) — the PrEP market is directly expanded. Structural losers: none clearly identifiable at this stage, but insurers may face short-term cost pressure. The legislative path is long: committee markup, floor vote, House passage, and potential conference. With a Democratic sponsor and all cosponsors from the Democratic party, passage requires bipartisan support in a divided Congress, which is uncertain. Near-term market impact is low unless the bill gains momentum.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Insurance mandate requiring private health plans to cover PrEP drugs without cost-sharing or preauthorization
Who must act
Private health insurers and group health plans subject to the Public Health Service Act and the Affordable Care Act
What happens
Increased prescription volume for PrEP drugs as cost barriers are removed, expanding the addressable patient population
Stock impact
Gilead's HIV segment (Truvada, Descovy) generates ~$15B annual revenue; the mandate directly expands utilization of its PrEP products, though the magnitude depends on current adherence gaps and insurer compliance
Matched on shared policy language across AI analyses, with ticker & timing weight
PrEP Access and Coverage Act of 2026
PrEP Assistance Program Act
PrEP and PEP are Prevention Act
MCKESSON CORPORATION: $15.2M Department of Justice Contract
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →